Updated February 2026active

PFAS Water Contamination Lawsuit Lawsuit

Preparing your case review…
Written By
People's Justice Legal Research Team
8 Cited SourcesFact-Checked15 min read
15,000+ Attorneys
$15B+ Recovered
No Upfront Fees
Qualification

Do You Qualify?

Eligibility Checklist

  • Documented exposure to PFAS-contaminated drinking water from a municipal system, private well, or military base installation
  • Lived, worked, or served on or near a military installation with confirmed PFAS contamination for 1 or more years
  • Diagnosed with kidney cancer (renal cell carcinoma), testicular cancer, thyroid cancer, thyroid disease, ulcerative colitis, liver cancer, or bladder cancer
  • Cancer or condition diagnosed after a period of sustained PFAS exposure, with medically plausible latency
  • Claim filed within applicable state statute of limitations (typically 2–3 years from diagnosis or discovery)
PFAS (per- and polyfluoroalkyl substances) are a group of more than 12,000 synthetic chemicals that have been used in manufacturing since the 1940s. They are called 'forever chemicals' because they do not break down in the environment or in the human body. PFAS were used extensively in aqueous film-forming foam (AFFF), the firefighting foam used at military bases and airports for decades. PFAS-contaminated AFFF has leached into groundwater near hundreds of military installations and civilian airports across the United States. PFAS were also discharged into waterways by industrial manufacturers — most notably DuPont's PFOA contamination of the Ohio River valley and Chemours' GenX contamination of the Cape Fear River in North Carolina. 3M manufactured PFOS-based PFAS and supplied them to the military and industry from the 1950s through 2002. Both companies concealed internal studies showing that PFAS accumulated in human blood and were linked to cancer. MDL 2873 — the AFFF Products Liability Litigation in the District of South Carolina — consolidates individual personal injury claims. The 3M water system settlement ($12.5B, 2023) and the DuPont/Chemours/Corteva water system settlement ($1.185B, 2024) have resolved municipal water utility claims but left individual personal injury claims unresolved. Individuals diagnosed with kidney cancer, testicular cancer, thyroid cancer, thyroid disease, ulcerative colitis, or other PFAS-linked conditions following documented exposure to contaminated drinking water may have significant individual claims.

Get Help Now

PFAS Water Contamination Lawsuit

Free consultation • No fees unless we win
How It Causes Harm

How PFAS "Forever Chemicals" in Drinking Water Cause Cancer and Disease

In Plain Language

Per- and polyfluoroalkyl substances (PFAS) are a class of synthetic fluorinated chemicals used in industrial processes, consumer products, and aqueous film-forming foam (AFFF) firefighting foam since the 1940s. Because the carbon-fluorine bond is one of the strongest in chemistry, PFAS do not break down in the environment or the human body — earning them the name "forever chemicals." When PFAS enter drinking water through industrial discharge, AFFF runoff, or contaminated groundwater, communities face decades of exposure through their tap water. Chronic ingestion causes progressive bioaccumulation in blood, liver, and kidneys, triggering a cascade of toxic mechanisms that have been linked to kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, pregnancy-induced hypertension, and immunosuppression.

Product: PFAS-contaminated drinking water / AFFF firefighting foamActive Ingredient: PFOA (perfluorooctanoic acid) / PFOS (perfluorooctane sulfonic acid) / GenX / PFBS
1

Serum Protein Binding and Organ Bioaccumulation

PFOA and PFOS bind tightly to serum albumin and liver fatty acid-binding proteins, concentrating in the liver, kidney, and blood. Unlike most environmental toxicants that are excreted within days, PFOA has a half-life of approximately 3.5 years in human serum and PFOS approximately 5 years. This means even modest ongoing exposure through contaminated drinking water results in steadily increasing body burdens over years and decades — with no biological mechanism for clearance unless exposure ceases entirely.

2

Endocrine Disruption and Thyroid Hormone Interference

PFAS structurally mimic thyroid hormones and compete with them for binding sites on serum transport proteins, particularly transthyretin. This interference suppresses free T4 and T3 levels, alters thyroid-stimulating hormone feedback, and disrupts the hypothalamic-pituitary-thyroid axis. Epidemiological studies of contaminated communities — including the C8 Health Project in Parkersburg, West Virginia — found significantly elevated rates of thyroid disease among residents with high PFOA serum levels. The C8 Science Panel found a probable link between PFOA exposure and thyroid disease.

3

Immune System Suppression and Reduced Vaccine Response

PFAS exposure is associated with dose-dependent suppression of antibody production following vaccination. Studies of Faroese children — a cohort with high seafood-related PFAS exposure — found that each doubling of PFAS serum concentration was associated with a 25–50% reduction in vaccine antibody titers against diphtheria and tetanus. Similar findings have been replicated in adult cohorts. The mechanism involves PFAS interference with B-cell and T-cell signaling pathways. In 2022, the National Toxicology Program concluded that PFAS are an immune hazard to humans.

4

Carcinogenicity — Kidney and Testicular Cancer

PFOA was classified as a Group 1 carcinogen (carcinogenic to humans) by the International Agency for Research on Cancer in November 2023, based on sufficient evidence from human epidemiology. The C8 Science Panel established probable links between PFOA exposure and kidney cancer and testicular cancer in the Mid-Ohio Valley population. PFOA promotes tumor formation through multiple pathways including PPAR-alpha activation (liver), oxidative stress, DNA damage response inhibition, and suppression of tumor suppressor gene expression. These mechanisms are dose-dependent and consistent across multiple epidemiological cohorts.

5

Developmental Toxicity and In Utero Exposure

PFAS cross the placental barrier and accumulate in umbilical cord blood and breast milk, exposing fetuses and newborns to maternal body burdens accumulated over years. In utero PFAS exposure has been associated with reduced birth weight, altered immune development, accelerated puberty in girls, and neurodevelopmental effects. Animal studies demonstrate fetal lethality, growth retardation, and skeletal deformities at high doses. The developing endocrine and immune systems are particularly vulnerable to disruption during critical windows of fetal development when PFAS cannot be cleared.

Danger Factors

  • Invisible Contamination — No Taste, No Odor: PFAS are odorless, colorless, and tasteless in water at concentrations far exceeding health thresholds. Communities in Parkersburg, West Virginia and Camp Lejeune, North Carolina consumed PFAS-contaminated water for decades without any sensory indication of contamination. Without systematic testing, residents have no means of detecting exposure. This invisibility meant that affected populations could not take protective action and continued to accumulate body burdens unknowingly.
  • Decades-Long Latency Before Diagnosis: Cancers linked to PFAS exposure — including kidney cancer and testicular cancer — typically have latency periods of 10 to 30 years from initial exposure to clinical diagnosis. This means residents exposed through contaminated municipal water in the 1980s and 1990s may only now be manifesting PFAS-related cancers. The long latency makes it difficult for individuals to connect their cancer to water contamination years or decades earlier, and complicates statute of limitations analysis.
  • Universal Exposure Through Drinking Water Infrastructure: Unlike occupational PFAS exposures limited to workers, contaminated municipal water systems expose entire communities — men, women, children, and infants — through drinking, cooking, bathing, and food preparation. EPA estimates that PFAS are detectable in drinking water serving over 200 million Americans. Populations near military bases, airports, and PFAS manufacturing facilities face the highest concentrations, but PFAS contamination has been detected in water systems across all 50 states.
  • Manufacturer Knowledge Predating Community Exposure: 3M's internal toxicology studies from 1975 documented that PFOS caused significant toxicity in animal models. DuPont's internal records from the 1960s acknowledged that C8 (PFOA) was toxic and bioaccumulative. Both companies continued manufacturing and selling PFAS products for decades without warning communities, regulators, or the public. The gap between manufacturers' internal knowledge and public disclosure — in some cases exceeding 30 years — is central to the mass tort claims.

Scientific Consensus

  • The International Agency for Research on Cancer classified PFOA as a Group 1 carcinogen in November 2023, the highest classification indicating sufficient evidence of human carcinogenicity.
  • The C8 Science Panel — an independent panel of epidemiologists funded by DuPont's settlement — found probable links between PFOA exposure and kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol, and pregnancy-induced hypertension.
  • The National Toxicology Program concluded in 2022 that PFAS are an immune hazard to humans based on consistent evidence of suppressed vaccine antibody responses across multiple study populations.
  • The EPA finalized Maximum Contaminant Levels of 4 parts per trillion for PFOA and PFOS individually in April 2024 — acknowledging no safe level of exposure — after decades of less protective health advisories.
  • Multiple large epidemiological studies have demonstrated dose-response relationships between PFAS serum concentrations and cancer incidence, immune dysfunction, and thyroid disruption, supporting biological plausibility of causation.

Why This Matters for Your Case

The harm mechanisms established by the C8 Science Panel, IARC, NTP, and independent epidemiologists provide the scientific foundation for PFAS water contamination litigation. Plaintiffs diagnosed with kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol, or pregnancy-induced hypertension who consumed contaminated drinking water can establish general causation through the C8 probable link findings and IARC's Group 1 classification. Specific causation requires evidence of PFAS exposure through contaminated water systems and, where possible, serum PFAS testing to document body burden.

Were you or a family member exposed to PFAS-contaminated water? Get a free case evaluation today.

Get Your Free Case Review

or call 1-800-555-0100

MDL 2873 — The AFFF Products Liability Litigation in Detail

In re: Aqueous Film-Forming Foams Products Liability Litigation (MDL 2873) is consolidated in the U.S. District Court for the District of South Carolina before Judge Richard Gergel. The MDL covers three distinct categories of claims: (1) municipal water system claims brought by public water utilities for the cost of PFAS remediation — resolved by the 3M and DuPont/Chemours/Corteva settlements; (2) personal injury claims brought by individuals diagnosed with PFAS-linked cancers and diseases; and (3) state claims. As of February 2026, more than 15,200 personal injury cases remain pending in MDL 2873. Bellwether personal injury trials have been scheduled for 2026. The court has appointed a Science and Technology Panel and conducted extensive Daubert proceedings on general causation for the injury categories: kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and other conditions. Unlike the Zantac MDL, MDL 2873 general causation expert testimony has survived Daubert challenge for the primary injury categories, giving PFAS personal injury claims a significantly stronger litigation posture than Zantac claims faced in federal court.

The Water System Settlements vs. Individual Personal Injury Claims

The landmark 3M and DuPont/Chemours/Corteva settlements were water utility settlements — they compensate public water systems for the cost of PFAS remediation (installing filtration systems, testing, cleanup). These settlements do not directly compensate individuals who were sickened by PFAS exposure. Individual personal injury claims — for kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and other conditions — are legally separate from the water system claims and proceed on their own track in MDL 2873. The scale of the water system settlements ($12.5 billion from 3M alone) demonstrates the defendants' enormous financial exposure and willingness to settle. This creates a favorable backdrop for individual personal injury settlement negotiations as bellwether trials approach in 2026.

Settlement Structure

PFAS Personal Injury Settlement Tiers by Injury Category

Individual PFAS personal injury settlement amounts depend on injury type, exposure documentation strength, and MDL bellwether trial outcomes. These estimates are based on the injury tier structure developed in MDL 2873 expert proceedings and comparable toxic tort litigation outcomes. The 3M water system settlement ($12.5B) and DuPont/Chemours/Corteva settlement ($1.185B) compensate water utilities, not individuals — individual personal injury claims are valued separately.

Tier 4 — Subclinical / Documented Exposure

Basic

Settlement Range

$100,000avg
$50,000$150,000

Criteria

  • Documented PFAS blood testing above EPA action levels
  • Elevated cholesterol or thyroid hormone disruption not meeting full disease threshold
  • Minor thyroid nodules not requiring surgery
  • Significant exposure documentation required
Tier III

Tier 3 — Thyroid Disease / Ulcerative Colitis

Moderate

Settlement Range

$225,000avg
$150,000$300,000

Criteria

  • Diagnosed thyroid disease (hypothyroidism, hyperthyroidism, Hashimoto's disease)
  • Ulcerative colitis requiring medication management
  • Non-cancer conditions with established PFAS epidemiological links from C8 Health Project research
Tier II

Tier 2 — Thyroid Cancer / Emerging Cancers

Severe

Settlement Range

$375,000avg
$250,000$500,000

Criteria

  • Diagnosed thyroid cancer, liver cancer, or bladder cancer with documented PFAS exposure
  • Strong exposure documentation and medical causation analysis required
  • Surgical treatment and ongoing surveillance factor into value
Tier I

Tier 1 — Kidney Cancer / Testicular Cancer

Critical

Settlement Range

$450,000avg
$300,000$600,000

Criteria

  • MDL 2873 bellwether injury categories with strongest epidemiological association to PFAS
  • Kidney cancer (renal cell carcinoma) and testicular cancer with strong exposure documentation
  • Stage, treatment intensity, and age affect the final value

These are pre-trial estimates based on comparable toxic tort litigation and MDL 2873 case structure as of February 2026. Actual individual claim values will be established by MDL 2873 bellwether trial outcomes and any global resolution framework. Water system settlements from 3M and DuPont/Chemours/Corteva do not compensate individual claimants. Consult a PFAS litigation attorney for case-specific evaluation.

Exposure Profiles

Who Is Most at Risk: PFAS Water Contamination Exposure Profiles

PFAS contamination of drinking water affects communities across the United States, but exposure intensity varies significantly based on proximity to contamination sources, duration of residence, and reliance on affected water systems. The following profiles identify the populations at greatest risk of PFAS-related health effects and the characteristics that define their exposure. All profiles assume chronic exposure through municipal or private well drinking water as the primary pathway.

Military Personnel and Veterans at AFFF-Using Bases

Combined occupational and residential — AFFF direct contact plus contaminated base drinking water

High Risk

Common Tasks

  • Living or working on military installations with AFFF-contaminated groundwater
  • Drinking water from base water systems drawing from PFAS-contaminated aquifers
  • Participation in or proximity to AFFF fire training exercises
  • Showering, cooking, and food preparation using base water supplies
  • Extended tours of duty (3–20+ years) at contaminated installations

Key Stat: The DoD has confirmed PFAS contamination at more than 455 military installations. Veterans who lived or worked on these bases for extended periods face dual exposure pathways: direct AFFF contact during training and continuous ingestion through contaminated drinking water. Studies of military communities near AFFF-heavy bases have documented PFAS serum levels 2–5 times higher than the general population. Installations with the longest AFFF use histories — including Peterson SFB, Wurtsmith AFB, and Pease Air Force Base — have produced the highest documented PFAS exposure levels.

Civilian Residents Near Contaminated Municipal Water Systems

Residential — long-term ingestion of PFAS-contaminated municipal drinking water

High Risk

Common Tasks

  • Drinking tap water from municipal systems drawing from PFAS-contaminated sources
  • Cooking with tap water (soups, pasta, coffee, baby formula preparation)
  • Brushing teeth and bathing with PFAS-contaminated water
  • Consuming locally grown produce irrigated with contaminated water
  • Residing in affected communities for 10 or more years

Key Stat: The EPA estimates that PFAS contaminate public drinking water systems serving approximately 200 million Americans. Residents of communities near military bases, PFAS manufacturing facilities, and airports face the highest concentrations. The Parkersburg, West Virginia community adjacent to DuPont's Washington Works plant is the most studied, with 69,000 residents enrolled in the C8 Health Project. Studies consistently find that duration of residence is positively correlated with serum PFAS levels and disease incidence.

Firefighters with AFFF Occupational Exposure

Occupational — direct AFFF contact during firefighting and training plus residential water exposure

High Risk

Common Tasks

  • Using AFFF foam during structural fire suppression and petroleum fire response
  • Conducting fire training exercises at facilities where AFFF is applied to training areas
  • Skin contact with AFFF-contaminated equipment, gear, and surfaces
  • Cleaning AFFF foam from equipment without adequate protective equipment
  • Residing in communities where fire training sites have contaminated groundwater

Key Stat: Firefighters face dual exposure pathways: occupational direct AFFF contact and residential exposure through contaminated community water systems near fire stations and training facilities. Studies of career firefighters have documented elevated PFAS serum levels and increased cancer incidence compared to the general population. The International Association of Firefighters has identified PFAS as a significant cancer risk factor for members. Skin absorption during AFFF foam contact is a documented exposure pathway beyond ingestion.

Workers at PFAS Manufacturing Facilities

Occupational — workplace air and dermal PFAS exposure plus contaminated local water

High Risk

Common Tasks

  • Working in production, quality control, or maintenance roles at PFAS manufacturing plants
  • Inhalation of PFAS aerosols, dust, and fumes in production areas
  • Skin contact with PFAS process chemicals without adequate protective equipment
  • Consuming food and water in contaminated break areas or facility cafeterias
  • Residing in communities near manufacturing facilities with contaminated groundwater

Key Stat: 3M workers at Cottage Grove, Minnesota had serum PFOS levels 1,000 times higher than the general population per 3M's own 1975 internal studies. DuPont workers at Washington Works in Parkersburg, West Virginia had documented PFOA body burdens associated with elevated disease rates across all six C8 probable-link categories. PFAS manufacturing workers represent a defined occupational exposure group with documented employer knowledge of risk — supporting failure-to-warn and workers' compensation claims distinct from community water contamination suits.

Residents Near PFAS Industrial Sites and Landfills

Residential — contaminated private wells and groundwater near industrial discharge sites

Moderate Risk

Common Tasks

  • Drinking water from private wells drawing from PFAS-contaminated aquifers
  • Using well water for all household purposes — cooking, bathing, irrigation
  • Living within a 5-mile radius of PFAS manufacturing plants, airports, or landfills receiving PFAS waste
  • Long-term residence with no alternative water supply
  • Limited or no knowledge of contamination due to lack of public notification

Key Stat: Private well users near industrial PFAS sites face particular risk because they are not served by municipal treatment systems and may lack the resources or awareness to test their water. EPA surveys have found PFAS in private wells across 30+ states, with the highest concentrations near industrial discharge sites, landfills that accepted PFAS-containing waste, and former AFFF training areas. Unlike municipal water customers who have legal rights against water utilities and manufacturers, private well users often must pursue claims directly against the industrial source of contamination.

Understanding Exposure Levels

High Risk (>70 ppt serum PFAS equivalent)
Chronic — daily exposure over 5 or more years through primary drinking water source(Populations in this category include long-term residents of Parkersburg WV, communities adjacent to high-use AFFF military installations, and current or former PFAS manufacturing workers. C8 Science Panel disease associations are strongest at serum levels in this range. All six probable-link diseases apply.)
Moderate Risk (20–70 ppt serum PFAS equivalent)
Ongoing — regular exposure through municipal water systems with PFAS detection above EPA health advisory but below MCL threshold(Populations include residents of communities with PFAS-contaminated municipal water systems that have not yet achieved the 2024 EPA MCL of 4 ppt. Duration of exposure is the key variable — moderate exposure over 20+ years can produce health effects comparable to shorter high-level exposure. Thyroid disease and high cholesterol associations are relevant at this exposure level.)
Background Risk (4–20 ppt serum PFAS equivalent)
Periodic — exposure through food, food packaging, and water systems with low-level PFAS detection(The entire U.S. population has measurable PFAS serum levels due to ubiquitous environmental contamination. Individuals at background exposure levels have much lower litigation standing than those with documented high-level water system exposure, but remain relevant for aggregate public health analysis. The 2024 EPA MCL of 4 ppt was set at the lowest feasible measurable level, acknowledging no safe threshold.)

Exposure profiles are based on publicly available epidemiological research, C8 Science Panel findings, DoD contamination disclosures, and EPA data. Individual risk assessment requires evaluation of specific water system contamination levels, duration of residence, serum PFAS testing where available, and diagnosed health conditions. This information does not constitute medical or legal advice. Individuals who believe they have been exposed to PFAS-contaminated drinking water should consult a qualified attorney.

Internal Documents

Internal Documents & Evidence

1975-06-01Source: Internal 3M corporate toxicology studies (obtained through MDL 2873 litigation discovery)

3M Internal 1975 Toxicology Memos: PFOS Toxicity Known for 25 Years Before Phaseout

Internal 3M studies conducted in 1975 confirmed that PFOS levels in the blood of production workers at 3M's Cottage Grove, Minnesota manufacturing facility were approximately 1,000 times higher than levels measured in the general population. Company toxicologists characterized PFOS as exhibiting significant toxicity in animal models and recommended the compound "should be regarded as toxic." Despite these unambiguous internal findings, 3M continued manufacturing PFOS-containing products — including AFFF firefighting foam — for an additional 25 years without disclosing the known health risks to workers, fire departments, military personnel, regulatory agencies, or the communities whose water systems were contaminated by AFFF training exercises.

Impact: The 1975 internal memos are among the most damaging pieces of corporate knowledge evidence in the PFAS litigation. They establish that 3M had actual, documented knowledge of PFOS toxicity a quarter-century before the company announced a "voluntary" phaseout in 2000. The 25-year concealment window supports claims of willful and wanton disregard for human health, provides a basis for punitive damages, and directly refutes any defense that 3M lacked awareness of PFAS health risks during the decades when contamination of community water systems was occurring.

2012-04-15Source: C8 Science Panel — independent epidemiological panel convened under Leach v. E.I. du Pont de Nemours & Co. settlement

DuPont C8 Medical Panel Findings: Six Probable-Link Diseases Established

After eight years of analyzing health data from 69,000 Mid-Ohio Valley residents exposed to PFOA (C8) through contaminated drinking water from DuPont's Washington Works plant, the C8 Science Panel published findings establishing probable links between PFOA exposure and six specific diseases: kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol (hypercholesterolemia), and pregnancy-induced hypertension (preeclampsia). The panel — comprising seven independent epidemiologists with no prior relationship to DuPont — applied a predetermined standard of scientific evidence before finding a probable link, meaning these findings represent conservative conclusions from a rigorous, adversarially-negotiated scientific process. DuPont agreed under the settlement to pay for class members' medical monitoring if the panel found probable links; it did, triggering that obligation.

Impact: The C8 Science Panel findings are the most frequently cited body of PFAS epidemiological evidence in mass tort litigation. Because they emerged from a court-supervised scientific process with agreed-upon methodology, they are difficult to challenge in court and provide strong general causation support for plaintiffs diagnosed with any of the six linked diseases. The panel's findings directly informed the EPA's development of PFAS health advisories and contributed to the evidence base for IARC's 2023 PFOA Group 1 carcinogen classification.

2000-04-01Source: U.S. EPA Region 4 inspection records and regulatory correspondence (public records)

EPA PFAS Testing at 3M Decatur, Alabama Plant Reveals Industrial Discharge

EPA Region 4 inspections and testing at 3M's Decatur, Alabama manufacturing facility — which produced PFOS for decades — revealed that the plant had discharged PFAS into the Tennessee River and adjacent groundwater at concentrations far exceeding any level the EPA would later consider safe. Community water systems drawing from the Tennessee River downstream of the Decatur plant showed elevated PFAS concentrations. The EPA's correspondence with 3M following the inspection, obtained through FOIA requests and litigation discovery, reveals that 3M's representatives downplayed the health significance of measured PFAS levels while simultaneously conducting internal studies indicating significant toxicity — precisely the disconnect between public representations and internal knowledge that defines failure-to-warn liability.

Impact: The Decatur plant records establish a direct line between 3M's manufacturing operations, environmental discharge, and community water supply contamination. They demonstrate that regulators who relied on 3M's representations about PFAS safety were misled, and that the company's voluntary compliance assurances masked ongoing discharges. These records also support Superfund cost-recovery claims against 3M for remediation of contaminated water systems and groundwater in communities downstream of the Decatur facility.

1970-01-01Source: AFFF manufacturer internal research documents (obtained through MDL 2873 discovery — In re: Aqueous Film-Forming Foam Products Liability Litigation, D.S.C.)

AFFF Manufacturer Documents Confirm Known Environmental Persistence Before Mass Use

Internal research documents from AFFF manufacturers — including 3M, Chemguard, National Foam, and Buckeye Fire Equipment — confirm that these companies understood the environmental persistence of PFAS-containing foam formulations before they became standard equipment at military bases and commercial airports. Internal technical memoranda acknowledge that PFAS compounds do not biodegrade in soil or water and will accumulate at training sites over time. Despite this knowledge, manufacturers marketed AFFF as environmentally safe for decades, and the Department of Defense was never warned that routine training exercises would result in permanent groundwater contamination at hundreds of military installations.

Impact: These manufacturer documents directly undercut the state-of-the-art defense — the argument that environmental persistence was unknowable at the time of manufacture and sale. They establish pre-market knowledge of the core property (non-biodegradability) that makes PFAS contamination permanent and communities' exposure ongoing. This evidence is critical to establishing that the transition from military to civilian water contamination was foreseeable and that manufacturers bore a duty to warn the Department of Defense and local communities about the permanent contamination risk.

2012-10-01Source: C8 Science Panel published studies — Frisbee et al. (2009), Steenland et al. (2010), Barry et al. (2013) — peer-reviewed epidemiology journals

C8 Science Panel Cancer Linkage Studies: Dose-Response Relationships Confirmed

A series of peer-reviewed epidemiological studies published by C8 Science Panel researchers established dose-response relationships between serum PFOA levels and incidence of kidney cancer and testicular cancer in the exposed Mid-Ohio Valley population. The Steenland et al. study found that each unit increase in PFOA serum concentration was associated with a statistically significant increase in kidney cancer incidence. The Barry et al. analysis confirmed the testicular cancer association across multiple study windows. Critically, these studies demonstrated that the cancer-PFOA association strengthens with increasing serum concentration — the hallmark of a dose-response relationship that is a cornerstone of causation analysis in toxic tort litigation.

Impact: Dose-response evidence is the most powerful form of epidemiological causation evidence available in mass tort cases. The C8 panel studies provide PFAS plaintiffs with peer-reviewed, court-tested data demonstrating that higher PFOA exposure is associated with higher cancer rates — directly linking the magnitude of community water contamination to the magnitude of harm. These studies have been replicated in independent cohorts and cited by IARC, EPA, and NTP, making them virtually unassailable as general causation evidence for kidney and testicular cancer PFAS claims.

Were you or a family member exposed to PFAS-contaminated water? Get a free case evaluation today.

Get Your Free Case Review

or call 1-800-555-0100

Regulatory Actions

PFAS Regulatory Timeline: From Industry Self-Regulation to Federal Enforceable Standards

The regulatory history of PFAS reflects decades of industry resistance to government oversight, voluntary phaseouts that fell far short of protective action, and a slow accumulation of scientific consensus that ultimately compelled the EPA to issue the first enforceable federal drinking water standards for PFAS in April 2024. The 80-year gap between PFAS synthesis in the 1940s and binding federal regulation in 2024 — during which manufacturers concealed internal toxicology data — forms the core of plaintiffs' regulatory negligence and failure-to-warn claims.

EPA2016medium

PFOA/PFOS Lifetime Health Advisory (70 ppt)

Advisory (non-enforceable)

The EPA issued a lifetime health advisory of 70 parts per trillion combined for PFOA and PFOS — the first federal guidance on PFAS in drinking water. The advisory was non-enforceable and applied only to public water systems, not private wells. Critics noted that the 70 ppt standard was set based on cancer risk models that may have underestimated actual risk. The advisory triggered public awareness of PFAS contamination at military bases and industrial sites but provided no legal requirement for remediation or cleanup.

EPA2024high

Final PFAS Maximum Contaminant Level Rule (4 ppt PFOA; 4 ppt PFOS)

Enforceable Federal Standard

In April 2024, the EPA finalized the first-ever enforceable Maximum Contaminant Levels for PFAS in public drinking water. The rule set individual MCLs of 4 ppt for PFOA and PFOS — a 94% reduction from the prior 70 ppt advisory. The rule also established MCLs for PFNA, PFHxS, and HFPO-DA (GenX), and a Hazard Index for PFNA/PFHxS mixtures. Water systems must achieve compliance by 2029. The EPA estimated the rule would reduce PFAS exposure for approximately 100 million Americans and prevent thousands of cancers over time.

Department of Defense2020high

AFFF Disclosure Requirements and PFAS Inventory at Military Installations

Federal Compliance Requirement

Following congressional pressure and litigation, the Department of Defense was required to disclose PFAS contamination at military installations and report results to Congress. The DoD identified PFAS contamination at more than 455 military installations — including 120+ with confirmed contamination of drinking water on or near the base. The DoD also began transitioning away from PFAS-containing AFFF to fluorine-free alternatives, though the transition has been slow due to performance concerns.

IARC2023medium

PFOA Classified as Group 1 Carcinogen (Carcinogenic to Humans)

International Scientific Classification

In November 2023, the International Agency for Research on Cancer upgraded PFOA from Group 2B (possibly carcinogenic) to Group 1 (carcinogenic to humans) — the highest classification. IARC found sufficient evidence from human studies of associations with kidney cancer and testicular cancer, and strong mechanistic evidence. PFOS was simultaneously upgraded to Group 2A (probably carcinogenic to humans). This classification change significantly strengthened general causation evidence available to PFAS plaintiffs.

3M / EPA2023high

3M $12.5B Water System Settlement

Civil Settlement

In June 2023, 3M reached a landmark $10.3 billion settlement with U.S. public water systems to resolve claims that 3M's PFAS-containing AFFF contaminated drinking water. The settlement was later increased to approximately $12.5 billion after additional utilities joined. Payments are structured over 13 years. The settlement resolved claims by approximately 300 water utilities and public water systems but did not include personal injury claims from individuals diagnosed with PFAS-related cancers.

DuPont / Chemours / Corteva2023medium

DuPont/Chemours/Corteva $1.185B Water System Settlement

Civil Settlement

In June 2023, DuPont, Chemours, and Corteva Agriscience settled water utility PFAS contamination claims for $1.185 billion. DuPont's settlement followed its spinoff of Chemours in 2015 and Corteva in 2019, with the three companies sharing liability for PFAS manufactured and discharged during the DuPont era. The settlement covered approximately 70% of the eligible water utilities nationwide but excluded personal injury plaintiffs.

EPA2022medium

PFAS Superfund Designation (CERCLA Hazardous Substances)

Federal Regulatory Designation

In 2022, the EPA proposed designating PFOA and PFOS as hazardous substances under CERCLA (the Superfund law), which would require cleanup of contaminated sites and enable cost recovery from responsible parties. The final designation was expected to trigger billions in cleanup costs at hundreds of contaminated military and industrial sites. PFAS Superfund sites have been identified in nearly every state, with cleanup costs estimated to exceed $400 billion nationally.

FDA2024medium

PFAS Food Packaging Phaseout

Regulatory Action

The FDA worked with manufacturers to voluntarily phase out PFAS-containing food packaging, including grease-resistant paper, fast food wrappers, and microwave popcorn bags. By 2024, major food packaging PFAS uses had been substantially eliminated. While this addresses a non-water exposure pathway, it confirms regulatory acknowledgment that PFAS exposures across all pathways must be reduced. The phaseout followed years of FDA testing that detected PFAS migration from packaging into food.

Significance Legend

High
Medium
Low

Key Takeaway

The regulatory record demonstrates that 3M and DuPont possessed internal evidence of PFAS toxicity for decades before federal standards were enacted. The 2024 EPA MCL rule — setting a near-zero threshold of 4 ppt — confirms that any level of PFOA or PFOS in drinking water poses a meaningful cancer risk. The multi-billion-dollar water utility settlements establish corporate causation and ability to pay, while leaving the personal injury litigation track open for affected individuals.

Corporate Impact

3M and DuPont's Decades of PFAS Concealment: What Corporate Records Reveal

The PFAS water contamination crisis is not an accident of unknowable science — it is the direct result of deliberate corporate decisions by 3M Company and DuPont de Nemours to manufacture and sell PFAS products while concealing internal evidence of their toxicity. Internal documents obtained through litigation discovery reveal that both companies possessed detailed knowledge of PFAS bioaccumulation, toxicity, and environmental persistence dating to the 1950s and 1960s — yet continued producing PFAS for decades while suppressing, minimizing, and failing to disclose that knowledge to regulators, workers, and the communities whose drinking water they contaminated.

$12.5B
3M Water System Settlement
Paid to U.S. water utilities over 13 years
455+
Contaminated Military Installations
DoD-confirmed PFAS sites across the U.S.
200M+
Americans with PFAS in Drinking Water
EPA estimate of individuals served by affected systems
70 years
Gap Between Synthesis and Federal Standard
3M began PFAS production in 1947; EPA MCL enacted in 2024
Group 1
IARC Carcinogen Classification (PFOA)
Highest classification — carcinogenic to humans (2023)

Timeline: 3M Company / DuPont / Chemours / Corteva

1947-01-01

3M Synthesizes PFOS; Electrochemical Fluorination Era Begins

3M Company begins commercial production of PFOA and PFOS using electrochemical fluorination at its Cottage Grove, Minnesota facility. These compounds become the chemical backbone of Scotchgard fabric protector, Teflon non-stick coatings (licensed to DuPont), and AFFF firefighting foam. Neither company discloses that internal animal studies from the outset are generating troubling toxicology signals.

1961-01-01

DuPont Internal Memo Flags C8 (PFOA) Toxicity

DuPont's own toxicologists document in internal memoranda that C8 (PFOA), the chemical used to manufacture Teflon at Washington Works in Parkersburg, West Virginia, is "toxic" in animal studies. Despite this internal finding, DuPont continues discharging PFOA into the Ohio River and atmosphere, contaminating the drinking water of communities in the Mid-Ohio Valley for decades.

1975-01-01

3M Internal Toxicology Memos Confirm PFOS Toxicity in Workers

3M's internal studies confirm that PFOS levels in the blood of 3M production workers are approximately 1,000 times higher than in the general population. Company toxicologists conclude internally that PFOS should be regarded as toxic based on animal study results. This information is not shared with the EPA, OSHA, or the workers themselves for more than two decades.

1980-01-01

DuPont Conceals Birth Defects Cluster Among PFOA-Exposed Workers

Two of eight pregnancies among female workers with direct PFOA exposure at DuPont's Washington Works plant result in children born with facial birth defects. DuPont's medical department documents the cluster internally but does not report the findings to regulators, affected workers, or the public. This concealment continues for more than two decades until Robert Bilott's litigation compels document disclosure.

2000-05-01

3M Announces Voluntary PFOS Production Phaseout — But Only After EPA Pressure

In May 2000, following EPA intervention, 3M announces a voluntary phaseout of PFOS and PFOA production. The announcement comes 25 years after 3M's internal toxicology memos confirmed worker blood levels 1,000 times above normal. 3M frames the phaseout as a voluntary safety measure; internal documents show the decision followed sustained EPA pressure and concern about pending regulatory action. The phaseout affects 3M's Scotchgard product line.

2004-01-01

C8 Health Project Reveals Mass Contamination; DuPont Settles Class Action

Under the terms of a class action settlement negotiated by attorney Robert Bilott, DuPont funds the C8 Health Project — a comprehensive health study of 69,000 Mid-Ohio Valley residents exposed to PFOA through contaminated water. The C8 Science Panel — seven independent epidemiologists — is established to review the data and determine probable links between PFOA exposure and specific diseases. DuPont agrees to pay all medical monitoring costs for class members if the panel finds probable links.

2012-01-01

C8 Science Panel Finds Probable Links to Six Diseases

After eight years of study, the C8 Science Panel publishes findings establishing probable links between PFOA exposure and kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol, and pregnancy-induced hypertension. These six diseases form the basis of personal injury lawsuits in the PFAS litigation. The panel's findings represent the most rigorous epidemiological analysis of PFAS health effects ever conducted and are widely cited in subsequent litigation and regulation.

2023-06-01

3M Agrees to $10.3B Water System Settlement; DuPont/Chemours Settle for $1.185B

3M reaches a landmark settlement of approximately $10.3 billion (later increased to $12.5 billion) with U.S. public water systems to resolve PFAS contamination claims, structured over 13 years. DuPont, Chemours, and Corteva simultaneously announce a $1.185 billion settlement with water utilities. Personal injury claims from individuals diagnosed with PFAS-related cancers remain unresolved and are proceeding in MDL litigation. The combined water utility settlements exceed $13.5 billion — the largest environmental settlements in U.S. history.

Dark Waters, Congressional Investigations, and the C8 Science Panel

The PFAS contamination scandal became a defining case study in corporate environmental malfeasance. Attorney Robert Bilott's 20-year legal campaign against DuPont — chronicled in the 2019 film Dark Waters and Nathaniel Rich's New York Times Magazine investigation — exposed how DuPont's own scientists had flagged PFOA toxicity since the 1960s while the company discharged the chemical into communities' drinking water. Congressional investigations in 2019 and 2020 revealed that 3M and DuPont had shared internal PFAS health data with each other through industry groups while withholding it from regulators. The C8 Health Project — funded by DuPont's settlement — exposed 69,000 West Virginia and Ohio residents to PFAS monitoring and produced the most comprehensive epidemiological evidence of PFAS health effects available, ultimately establishing the six probable-link diseases that anchor personal injury litigation.

  • 2019 film Dark Waters (starring Mark Ruffalo as attorney Rob Bilott) brings PFAS contamination to national public attention and triggers surge in litigation inquiries
  • 2019–2020 congressional hearings reveal 3M and DuPont shared PFAS toxicology data internally through industry associations while withholding from EPA
  • Chemours Fayetteville Works facility in North Carolina found discharging GenX (HFPO-DA) into Cape Fear River — contaminating drinking water for Wilmington and surrounding communities
  • 3M faces $10.3 billion water utility settlement in 2023 after litigation reveals the company knew of PFOS toxicity from 1975 internal memos and withheld findings for 25 years
  • National Toxicology Program 2022 report concludes PFAS are an immune hazard to humans — contradicting decades of industry claims that PFAS were safe at real-world exposure levels

Credit Rating Actions

S&P Global
Downgrade Watch (3M, 2023)
Placed 3M on negative watch following $10.3B water utility settlement announcement pending assessment of personal injury litigation exposure
Moody's
Baa1 with Negative Outlook (Chemours, 2022)
Cited PFAS remediation obligations, regulatory uncertainty, and GenX litigation as ongoing credit risks for Chemours following DuPont spinoff
Fitch
BBB with Stable Outlook (DuPont, 2023)
Noted that the $1.185B water utility settlement with Chemours/Corteva reduced DuPont's most acute PFAS liability but flagged continued uncertainty from PFAS personal injury MDL litigation

Key Takeaway

3M and DuPont possessed internal evidence of PFAS toxicity — including worker blood level anomalies, birth defects clusters, and animal tumor studies — for decades before taking protective action. The 70-year timeline from first PFAS synthesis to enforceable federal drinking water standards, and the billions in corporate settlements that have already been paid, establish that PFAS water contamination was a foreseeable and preventable harm caused by deliberate corporate decisions to prioritize profits over public health.

Case Results

Notable Verdicts & Settlements

Verdict

In June 2023, 3M Company agreed to pay $10.3 billion to $12.5 billion — the final amount contingent on the number of participating water systems — to resolve claims by U.S. public water utilities for PFAS contamination of municipal drinking water supplies. The settlement is allocated to help water systems finance PFAS testing, monitoring, and filtration. This landmark settlement is one of the largest environmental settlements in U.S. history and constitutes an implicit acknowledgment by 3M of its responsibility for widespread PFAS contamination. The 3M settlement covers water system remediation costs and does not compensate individual personal injury claimants.

Verdict

In 2024, DuPont de Nemours, Chemours Company, and Corteva Inc. agreed to pay $1.185 billion to resolve claims by U.S. municipal water systems for PFAS contamination. The three companies — the successors to DuPont's legacy chemical operations — reached this settlement as a companion to the earlier 3M agreement, together creating a combined water system settlement exceeding $13.5 billion. The DuPont/Chemours/Corteva settlement does not resolve individual personal injury claims by people sickened by PFAS exposure, which remain pending in MDL 2873.

Verdict

In 2017, DuPont and its spinoff Chemours agreed to pay $671 million to settle approximately 3,500 personal injury claims by residents of the Mid-Ohio Valley who were exposed to PFOA (C8) contamination from DuPont's Washington Works plant. The settlement followed the C8 Health Project findings and several bellwether trials, including the 2016 jury verdict in Bartlett v. DuPont awarding $5.1 million to an Ohio woman with kidney cancer. This settlement established a precedent for per-claimant PFAS personal injury values and formed the model for MDL 2873 personal injury resolution frameworks.

Verdict

In 2016, an Ohio federal jury awarded $5.1 million to Carla Bartlett, a PFOA-exposed Ohio resident who developed kidney cancer after years of drinking PFOA-contaminated water from the DuPont Washington Works discharge zone. Bartlett was the first C8 bellwether trial verdict and became a landmark result establishing that PFOA causes kidney cancer and that DuPont concealed its knowledge of the health risks. The Bartlett verdict helped precipitate DuPont's $671 million C8 personal injury settlement in 2017.

Verdict

In 2004, DuPont agreed to pay $70 million and fund the C8 Health Project — a comprehensive epidemiological study of 69,000+ PFOA-exposed residents — to settle a class action by Mid-Ohio Valley residents whose drinking water was contaminated by PFOA discharge from Washington Works. The settlement's requirement that DuPont fund an independent science panel to study PFOA health effects was pivotal: it produced the C8 Science Panel reports (2012) establishing the causal links between PFOA and kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol, and pregnancy-induced hypertension that form the foundation of all subsequent PFAS personal injury litigation.

Verdict

In 2021, Saint-Gobain Performance Plastics and Honeywell International agreed to pay approximately $65 million to settle claims by residents of Hoosick Falls, New York, whose drinking water was contaminated with PFOA from a nearby plastics manufacturing facility. The settlement compensated approximately 1,500 residents for medical monitoring, property damage, and personal injury claims. Separately, in 2020, DuPont agreed to pay $28 million to settle Hoosick Falls claims arising from its supply of PFOA to the Saint-Gobain facility. The Hoosick Falls litigation is notable as one of the first non-military PFAS personal injury settlements and provided an early benchmark for per-claimant PFAS recovery values.

Were you or a family member exposed to PFAS-contaminated water? Get a free case evaluation today.

Get Your Free Case Review

or call 1-800-555-0100

Medical Condition

Kidney Cancer (Renal Cell Carcinoma)

Medical Definition

Kidney cancer — specifically renal cell carcinoma (RCC) — is the MDL 2873 Tier 1 bellwether injury with the strongest epidemiological association to PFAS exposure. PFAS accumulate in kidney tissue and disrupt cell signaling pathways involved in tumor suppression. Multiple large-cohort studies, including data from the C8 Health Project examining 69,000+ PFOA-exposed individuals in West Virginia and Ohio, have found significantly elevated rates of kidney cancer in people with high PFAS blood concentrations. The International Agency for Research on Cancer (IARC) classified PFOA as a Group 1 known human carcinogen in 2023, citing kidney cancer as one of the primary associated cancers. Renal cell carcinoma comprises approximately 90% of kidney cancers and has a strong dose-response relationship with PFOA and PFOS serum concentration in epidemiological research.

Symptoms

Blood in urine (hematuria) — often the first symptom

moderate

Persistent lower back or flank pain on one side

moderate

Unexplained weight loss of 10 or more pounds

moderate

Fatigue and general weakness

moderate

Low-grade fever not explained by infection

moderate

Swelling in the legs or ankles

moderate

Palpable mass in the abdomen or side (advanced disease)

moderate

Risk Factors

  • PFAS-contaminated drinking water exposure — strongest documented environmental risk factor
  • Smoking — independent risk multiplier
  • Obesity and high blood pressure
  • Family history of renal cell carcinoma or Von Hippel-Lindau disease
  • Occupational chemical exposure (trichloroethylene, cadmium)
  • Long-term dialysis for other kidney disease
Medical Condition

Testicular Cancer

Medical Definition

Testicular cancer has one of the strongest and most consistent epidemiological associations with PFAS exposure, particularly PFOS. Studies of AFFF-exposed firefighters and military personnel have found significantly elevated rates of testicular cancer, and multiple national cohort studies link PFOS serum concentration to testicular cancer incidence. Testicular cancer primarily affects younger men (peak incidence age 15–35), meaning PFAS-exposed veterans and firefighters who developed testicular cancer may carry decades of lost earnings and quality-of-life damages. In MDL 2873, testicular cancer is a Tier 1 bellwether injury category alongside kidney cancer. PFOS and PFOA are thought to act as endocrine disruptors in testicular tissue, interfering with hormone signaling and Leydig and Sertoli cell function in ways that promote oncogenesis.

Symptoms

Painless lump or swelling in one testicle — most common first sign

moderate

Dull ache or feeling of heaviness in the scrotum

moderate

Breast tenderness or growth (gynecomastia from hormone-producing tumors)

moderate

Back pain or abdominal pain if cancer has spread to lymph nodes

moderate

Fluid collection in the scrotum

moderate

Risk Factors

  • PFAS-contaminated drinking water or AFFF occupational exposure
  • Military service or firefighting at PFAS-contaminated installations
  • Undescended testicle (cryptorchidism) — independent risk factor
  • Family history of testicular cancer
  • Young male (age 15–35 peak risk)
Medical Condition

Thyroid Disease and Thyroid Cancer

Medical Definition

Thyroid disease — including hypothyroidism, hyperthyroidism, Hashimoto's thyroiditis, and thyroid cancer — is strongly linked to PFAS exposure through the disruption of thyroid hormone signaling. PFAS molecules structurally resemble thyroid hormones and compete with them at binding sites, interfering with the production, transport, and metabolism of thyroxine (T4) and triiodothyronine (T3). Research from the C8 Health Project, Mount Sinai School of Medicine, and multiple European cohort studies has documented elevated rates of thyroid disease in PFAS-exposed populations. Women are disproportionately affected by PFAS-related thyroid disease because the thyroid gland is more active in women and thyroid autoimmune conditions are more prevalent in the female population. A 2018 Mount Sinai study found that higher serum PFAS concentrations were associated with significantly elevated thyroid cancer risk. In MDL 2873, thyroid disease (diagnosed hypothyroidism or hyperthyroidism requiring medication) is a recognized personal injury category, as is thyroid cancer. Ulcerative colitis — an inflammatory bowel condition linked to PFOA exposure in C8 data — is also recognized.

Symptoms

Unexpected weight gain or difficulty losing weight (hypothyroidism)

moderate

Fatigue, brain fog, and cold sensitivity (hypothyroidism)

moderate

Rapid or irregular heartbeat and anxiety (hyperthyroidism)

moderate

Goiter — swelling or lump in the neck

moderate

Voice changes or difficulty swallowing (thyroid cancer)

moderate

Enlarged lymph nodes in the neck (thyroid cancer spread)

moderate

Risk Factors

  • PFAS-contaminated drinking water exposure — thyroid disruption documented in multiple studies
  • Female sex — women are 3 times more likely to develop thyroid disease
  • History of radiation exposure to the neck
  • Family history of thyroid disorders or autoimmune disease
  • Iodine deficiency or excess (independent factor)
The Team

Your Legal Team

EB

Erin Brockovich

Erin Brockovich is the consumer advocate whose investigation of Pacific Gas and Electric's chromium-6 contamination of Hinkley, California groundwater resulted in a landmark $333 million settlement — the largest settlement in U.S. history for a direct-action lawsuit. Brockovich has been an active public voice on PFAS contamination, connecting with affected communities near military bases and industrial sites. Her advocacy organization works with plaintiff's attorneys to identify contaminated communities and connect residents with legal resources. While not a licensed attorney, Brockovich's environmental contamination expertise and community outreach have supported PFAS litigation efforts in multiple states including Colorado, Ohio, and Florida.

RB

Robert Bilott

Robert Bilott is a partner at Taft Stettinius & Hollister LLP in Cincinnati, Ohio and is widely regarded as the attorney who broke the DuPont PFOA contamination story. Beginning in 1998 with farmer Wilbur Tennant's case, Bilott uncovered DuPont's internal documents showing the company knew PFOA was accumulating in human blood and causing health effects for decades before warning the public. Bilott drove the creation of the C8 Health Project — the landmark 69,000-person epidemiological study that established the causal links between PFOA and kidney cancer, testicular cancer, thyroid disease, and ulcerative colitis. His work culminated in DuPont's $671 million C8 personal injury settlement in 2017. His account is documented in the 2019 film Dark Waters. Bilott continues to represent PFAS-exposed plaintiffs and has been a key architect of MDL 2873 litigation strategy.

ML

Michael London

Michael London is a principal at Douglas & London P.C. in New York City and serves on the Plaintiff Steering Committee in MDL 2873, coordinating personal injury claim strategy on behalf of thousands of individual PFAS claimants. London has extensive mass tort and toxic tort litigation experience, including asbestos, pharmaceutical, and environmental contamination cases. His firm has represented hundreds of PFAS personal injury clients — firefighters, veterans, military families, and contaminated community residents — pursuing kidney cancer, testicular cancer, and thyroid disease claims. London has worked with leading toxicology and epidemiology experts to develop and refine the general causation arguments that have survived Daubert challenge in MDL 2873, enabling the personal injury claims to proceed toward bellwether trials in 2026.

FAQ

Frequently Asked Questions

PFAS (per- and polyfluoroalkyl substances) are a group of more than 12,000 synthetic chemicals that have been manufactured and used in industrial and consumer products since the 1940s. They are called 'forever chemicals' because the carbon-fluorine bonds in their molecular structure are among the strongest in chemistry — they do not break down in the environment or in the human body. PFAS accumulate in soil, water, air, wildlife, and human blood and organs over time. The health risks from PFAS exposure have been documented in hundreds of epidemiological studies. PFAS are linked to kidney cancer, testicular cancer, thyroid cancer and disease, ulcerative colitis, liver disease, immune system disruption, pregnancy complications, and high cholesterol. PFAS act as endocrine disruptors — they interfere with hormone signaling — and accumulate in organs including the liver, kidneys, and thyroid. The International Agency for Research on Cancer (IARC) classified PFOA as a Group 1 known human carcinogen in 2023.
To qualify for a PFAS personal injury lawsuit, you generally need to meet three criteria. First, documented or provable exposure to PFAS-contaminated water: this typically means living or working near a military base, industrial facility, airport, or other PFAS source site for a sustained period, or using a municipal water system or private well that has tested positive for PFAS above EPA action levels. Second, a diagnosis of a qualifying medical condition: kidney cancer (renal cell carcinoma), testicular cancer, thyroid cancer, thyroid disease requiring medication, ulcerative colitis, liver cancer, or bladder cancer are the primary qualifying conditions in MDL 2873. Third, a medically plausible causal link between your exposure and your diagnosis, supported by the timeline of your exposure and the epidemiological evidence developed in MDL 2873. You do not need to have PFAS blood test results, though they are helpful — your attorney can help establish exposure through public contamination records and DoD disclosure data.
AFFF (aqueous film-forming foam) exposure and drinking water PFAS contamination are related but legally distinct pathways in PFAS litigation. AFFF exposure refers to direct occupational contact with AFFF firefighting foam — most commonly experienced by firefighters (military and civilian), airport ground crews, and industrial firefighting personnel who physically applied or trained with AFFF. This creates a particularly high-dose PFAS exposure pathway. Water contamination exposure refers to consuming or bathing in PFAS-contaminated tap water from a municipal system or private well that was contaminated by AFFF, industrial discharge, or other PFAS sources. Both pathways can result in PFAS bioaccumulation at levels associated with cancer and other disease. Both types of claims are consolidated in MDL 2873. The exposure pathway affects how causation is argued and what evidence documents exposure, but both can support individual personal injury claims for PFAS-linked cancers and conditions.
Individual PFAS personal injury settlement amounts have not yet been set by a global settlement program as of February 2026. MDL 2873 bellwether personal injury trials are scheduled for 2026 and will be the primary value-setting events for the individual claim pool. Based on the injury tier structure developed in MDL 2873 expert proceedings and comparable toxic tort litigation, estimated ranges are: kidney cancer and testicular cancer (MDL Tier 1 injuries with the strongest epidemiological links) — $300,000 to $600,000 or more depending on stage and treatment; thyroid cancer and other cancers — $250,000 to $500,000; thyroid disease and ulcerative colitis — $150,000 to $300,000; documented subclinical exposure with health effects — $50,000 to $150,000. These are pre-trial estimates. The $12.5 billion 3M settlement and $1.185 billion DuPont settlement compensate water utilities, not individual claimants — individual compensation is separate.
The U.S. Department of Defense has confirmed PFAS contamination at more than 700 military installations across the United States. The DoD used AFFF containing PFOS and PFOA for aircraft crash rescue and firefighting training for decades. When AFFF was applied during training exercises and emergencies, it soaked into the ground and contaminated groundwater. Notable contaminated installations include: Eielson Air Force Base, Alaska (334,200 ppt PFOS — among the highest recorded in the nation); Wright-Patterson AFB, Ohio; Peterson Space Force Base, Colorado; NAS Pensacola, Florida; Eglin AFB, Florida; Fort Carson, Colorado; JBLM (Joint Base Lewis-McChord), Washington; Vance AFB, Oklahoma; Marine Corps Base Camp Lejeune, North Carolina; and Pease Air National Guard Base, New Hampshire (one of the first confirmed military PFAS sites, confirmed 2014). Veterans, active-duty service members, their families, and civilians who lived or worked near these bases and consumed contaminated water may have legal claims.
Yes. In June 2023, 3M Company announced a settlement to pay $10.3 billion to $12.5 billion to U.S. public water systems to resolve claims for PFAS contamination of municipal drinking water supplies. This settlement, approved in MDL 2873 by Judge Richard Gergel in the District of South Carolina, is one of the largest environmental settlements in U.S. history. The funds are allocated to water utilities for the cost of PFAS testing and remediation — specifically, installing filtration systems to remove PFAS from drinking water. Separately, DuPont, Chemours, and Corteva agreed in 2024 to pay $1.185 billion to resolve additional water system PFAS claims. These landmark water system settlements are legally separate from individual personal injury claims — people sickened by PFAS exposure must pursue separate individual claims through MDL 2873.
MDL 2873 in the District of South Carolina is a multidistrict litigation — similar to a class action in that it consolidates thousands of related cases before a single judge for coordinated pretrial proceedings, but different in that each claimant maintains an individual claim rather than sharing equally in a class recovery. Individual PFAS personal injury claims are filed separately, with each claimant's damages based on their specific exposure history, diagnosis, and damages. There is no single class action settlement fund that individuals can simply submit a claim form to join as of February 2026. Claimants must file individual claims through an attorney to participate in MDL 2873 proceedings and any eventual settlement. Separate state-court PFAS cases and municipal water system cases are also pending across the country.
Several resources can help you determine whether your drinking water has been tested for PFAS. The Environmental Working Group (EWG) maintains an interactive PFAS contamination map at ewg.org/interactive-maps/pfas_contamination/ that shows thousands of confirmed PFAS contamination sites and tested water systems across the United States. The EPA's PFAS testing data from public water systems is publicly available through the Safe Drinking Water Information System. The Department of Defense publishes PFAS testing results for military installations and surrounding communities. If your water system has not been tested, you can purchase independent PFAS testing from certified environmental testing laboratories — look for labs certified under EPA Method 533 or EPA Method 537.1. If you use a private well, your county health department may offer testing resources. Water systems serving more than 3,300 people are now required to test for PFAS under EPA's April 2024 PFAS National Primary Drinking Water Regulation.
The statute of limitations for PFAS personal injury claims is typically 2 to 3 years from the date of a qualifying diagnosis — or from the date the claimant knew or should have known that their illness was caused by PFAS exposure (the discovery rule). Because PFAS contamination sites were often not publicly disclosed until DoD disclosure requirements took effect after 2016, and because many communities did not receive formal notification of PFAS contamination until 2018–2020, courts have been receptive to delayed discovery arguments for PFAS claimants. State limitations periods vary: California allows 3 years from discovery for environmental toxic tort claims; Florida allows 4 years for product liability with the discovery rule; Ohio and Colorado have 2-year limitations periods. MDL 2873 has also issued tolling orders that paused statutes of limitations for claimants who enrolled in the MDL before applicable cutoff dates. Consult a PFAS attorney immediately to evaluate your specific deadline.
The cancers most strongly and consistently linked to PFAS exposure in human epidemiological studies are: kidney cancer (renal cell carcinoma) — the MDL Tier 1 bellwether diagnosis; testicular cancer — particularly linked to PFOS and PFOA; thyroid cancer — associated with PFAS disruption of thyroid hormone signaling. Additional cancers with evidence of PFAS association include: liver cancer, bladder cancer, ovarian cancer, and non-Hodgkin lymphoma. In 2023, the International Agency for Research on Cancer (IARC) classified PFOA as a Group 1 known human carcinogen, citing sufficient evidence for kidney cancer in humans, and PFOS as a Group 2B possible human carcinogen. The C8 Health Project established the first comprehensive links between PFOA exposure and kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and high cholesterol in a population of 69,000+ exposed individuals.
Yes. PFAS exposure through contaminated drinking water affects anyone who consumed or used that water — renters, homeowners, and transient residents alike. Renters who lived in apartments, rental houses, or base housing near military installations are just as much at risk of PFAS exposure as homeowners in the same area. Your legal standing to file a PFAS claim is based on your exposure and your diagnosis — not on whether you owned or rented your home. Similarly, people who lived on military installations in base housing have PFAS claims regardless of whether they were service members, military spouses, or dependents. Workers who regularly consumed water at a contaminated workplace can also file PFAS claims. If you drank contaminated water for a sustained period and developed a qualifying condition, you may have a claim regardless of your property ownership status.
The primary defendants in PFAS water contamination litigation are: 3M Company — manufactured PFOS-based PFAS from the 1950s through 2002 and supplied PFAS to the military and industry; settled water system claims for $12.5 billion in 2023; individual personal injury claims remain pending. DuPont de Nemours — manufactured PFOA (C8) at Washington Works in West Virginia for decades; discharged PFOA into the Ohio River; settled water system claims as part of the 2024 $1.185 billion settlement with Chemours and Corteva. Chemours Company — a DuPont spinoff that inherited PFAS liabilities; continues to operate Fayetteville Works in North Carolina where GenX chemicals contaminate the Cape Fear River. Corteva — another DuPont spinoff with PFAS liabilities. AFFF manufacturers: Tyco Fire Products, Chemguard, Buckeye Fire Equipment, National Foam, Angus Fire, and others who manufactured AFFF using PFAS for the military and civilian markets. 3M's January 2023 announcement that it would exit PFAS manufacturing by end of 2025 was another acknowledgment of the scope of liability.
Filing Deadlines

PFAS Water Contamination Lawsuit Filing Deadlines

The statute of limitations for PFAS personal injury claims is typically 2 to 3 years from the date of a qualifying diagnosis — or from the date the claimant knew or reasonably should have known that their illness was caused by PFAS exposure. Because PFAS contamination was not widely publicized until 2016 (the Flint-era surge in water contamination coverage) and the EPA did not set enforceable maximum contaminant levels until April 2024, courts in many states have applied the discovery rule generously to PFAS claimants. MDL 2873 tolling agreements have also paused statutes of limitations for certain categories of claimants during the pendency of the MDL.

Discovery Rule and PFAS-Specific Tolling

PFAS personal injury claims are governed by the discovery rule in most states — the limitations clock begins when the claimant knew or should have known of both the injury and its likely PFAS cause. Because PFAS contamination sites were not publicly disclosed until DoD disclosure requirements took effect (post-2016), and because PFAS health effects were not broadly communicated to affected communities until 2018–2020, courts have been receptive to delayed discovery arguments for PFAS claimants with older diagnoses. Claimants who received cancer diagnoses from 2019 onward and who were not publicly informed of local PFAS contamination until DoD disclosures reached their community should consult an attorney about discovery rule arguments. MDL 2873 has also issued tolling orders that may extend deadlines for claimants who joined the MDL before certain cutoff dates. State-court PFAS claims not enrolled in the MDL are governed by their state's own limitations law without MDL tolling.

Bottom Line

If you were diagnosed with kidney cancer, testicular cancer, thyroid disease, or ulcerative colitis and have reason to believe you were exposed to PFAS-contaminated water — especially near a military base — consult a PFAS litigation attorney immediately. Statutes of limitations are unforgiving deadlines that permanently bar late claims.

Dive Deeper

In-Depth Guides

AFFF Firefighter PFAS Exposure Lawsuit

Firefighters — both military and civilian — who worked with AFFF aqueous film-forming foam face the highest documented PFAS body burdens of any occupational group. AFFF contains PFOS and PFOA at concentrations orders of magnitude higher than contaminated drinking water. Firefighters with kidney cancer, testicular cancer, or thyroid disease following AFFF exposure have strong individual claims in MDL 2873.

Read guide

PFAS Biosolids Farm Contamination Lawsuit

PFAS-contaminated biosolids (sewage sludge) spread as agricultural fertilizer have contaminated private wells and farmland across the United States — a largely invisible exposure pathway that is only now reaching litigation. Affected farmers, rural homeowners, and farmworkers in Maine, Iowa, Michigan, and Texas have active claims. This is one of the least-covered and fastest-growing fronts in PFAS litigation.

Read guide

GenX Chemicals Chemours Lawsuit — Cape Fear River

Chemours Company — a DuPont spinoff — has discharged GenX chemicals (HFPO-DA) from its Fayetteville Works facility in Bladen County, North Carolina into the Cape Fear River since 2006. Wilmington-area residents who drank Cape Fear River water have been exposed to GenX and other PFAS at concentrations far above EPA health advisory levels. This is among the largest active industrial PFAS contamination zones in the eastern United States, and it is significantly underserved by legal content.

Read guide

PFAS Kidney Cancer Lawsuit

Kidney cancer (renal cell carcinoma) is the MDL 2873 Tier 1 bellwether injury — the PFAS-linked condition with the strongest and most consistent epidemiological association. The IARC classified PFOA as a Group 1 known human carcinogen for kidney cancer in 2023. Individuals who developed kidney cancer after sustained PFAS exposure through drinking water have among the strongest claims in PFAS litigation.

Read guide

Military Base PFAS Contamination Lawsuit

More than 700 U.S. military installations have confirmed PFAS contamination from decades of AFFF firefighting foam use. Veterans, active-duty service members, military families, and civilian base employees who lived or worked on contaminated installations and developed kidney cancer, testicular cancer, or thyroid disease may have substantial legal claims. The DoD has confirmed contamination at bases in all 50 states.

Read guide

Military Bases with PFAS Contamination — Complete List

The Department of Defense has confirmed PFAS contamination at more than 700 U.S. military installations as of 2026. This page provides a state-by-state summary of confirmed contaminated bases and the communities affected. If you lived or served at a contaminated installation and developed a qualifying health condition, contact a PFAS attorney to evaluate your claim.

Read guide

PFAS Settlement Amounts Per Person

The $12.5 billion 3M settlement and $1.185 billion DuPont/Chemours/Corteva settlement compensate water utilities — not individuals. Individual PFAS personal injury settlement amounts depend on injury category, exposure documentation, and MDL 2873 bellwether trial outcomes. Kidney and testicular cancer claims are expected to produce the highest individual recoveries, estimated at $300,000 to $600,000 or more.

Read guide

PFAS Lawsuit Statute of Limitations by State

The statute of limitations for PFAS personal injury claims is typically 2 to 3 years from diagnosis or from when you discovered the PFAS-illness connection. Because military and industrial PFAS contamination was not publicly disclosed until 2016–2020 in most communities, courts have been receptive to delayed discovery arguments. Act now — deadlines are real, and missing them permanently bars your claim.

Read guide

PFAS Testicular Cancer Lawsuit

Testicular cancer is an MDL 2873 Tier 1 injury category with one of the strongest epidemiological links to PFAS — particularly PFOS exposure. The cancer predominantly affects younger men (age 15–35), meaning veterans and firefighters who developed testicular cancer after PFAS exposure at military installations often carry decades of lost earnings and quality-of-life damages. Claims in MDL 2873 are active and advancing toward bellwether trials in 2026.

Read guide

PFAS Thyroid Disease and Thyroid Cancer Lawsuit

PFAS disrupt thyroid hormone signaling by mimicking and competing with thyroid hormones at receptor and transport protein binding sites. Women are disproportionately affected. Diagnosed thyroid disease requiring medication (hypothyroidism, hyperthyroidism, Hashimoto's thyroiditis) and thyroid cancer are recognized injury categories in MDL 2873. A 2018 Mount Sinai study found significantly elevated thyroid cancer risk with higher serum PFAS concentrations.

Read guide

PFAS Ulcerative Colitis Lawsuit

Ulcerative colitis — a chronic inflammatory bowel disease — was one of the six conditions designated by the C8 Science Panel as having a probable link to PFOA exposure in the Mid-Ohio Valley study. This is a non-cancer qualifying condition recognized in MDL 2873 personal injury proceedings. Claimants with PFAS exposure and a confirmed ulcerative colitis diagnosis may have viable claims even without a cancer diagnosis.

Read guide

PFAS Drinking Water Contamination Lawsuit

PFAS-contaminated municipal water systems and private wells have exposed millions of Americans to dangerous concentrations of forever chemicals. Residents who drank contaminated tap water for years and developed kidney cancer, testicular cancer, or thyroid disease have individual claims in MDL 2873. You do not need to have lived near a military base — industrial and agricultural PFAS sources have contaminated water supplies across the country.

Read guide

Sources & References

  1. In re: Aqueous Film-Forming Foams Products Liability Litigation — MDL No. 2873, D.S.C.U.S. District Court, District of South Carolina [Link]
  2. PFAS Strategic Roadmap: EPA's Commitments to Action 2021–2024U.S. Environmental Protection Agency [Link]
  3. PFAS National Primary Drinking Water Regulation — Maximum Contaminant Levels (April 2024)EPA [Link]
  4. ATSDR PFAS Exposure and Health Effects MonographAgency for Toxic Substances and Disease Registry [Link]
  5. EWG PFAS Contamination Interactive MapEnvironmental Working Group [Link]
  6. 3M PFAS Water System Settlement — $10.3B to $12.5BD.S.C. MDL 2873, Settlement Order 2023
  7. DuPont, Chemours, Corteva PFAS Settlement — $1.185 BillionD.S.C. MDL 2873, Settlement Order 2024
  8. C8 Health Project — PFOA Exposure and Health Effects in Mid-Ohio ValleyWest Virginia University / C8 Science Panel, 2005–2013